Latest study finds a new purpose for an existing drug for colorectal cancer treatment.

In a recent new study published in the journal Cell Death & Disease, lab head Dr. Ashwini Chand and then PhD student Dr. Rhynelle Dmello, discovered that Bazedoxifene shows remarkable potential as an anti-cancer agent against colorectal cancer. This occurs via a mode-of-action distinct from the original purpose of the drug to function a modulator of estrogen signalling.

“This study is based on our previous discovery that Bazedoxifene also blocks the action of two major pro-inflammatory signalling molecules known as IL-6 and IL-11,” said Dr. Chand.

Dr. Dmello, the first author on the paper adds, “In addition to the potent suppression of cancer growth in human colorectal cancer models we observe with Bazedoxifene treatment on its own, we excitingly define drug combinations that further boost the killing efficiency of Bazedoxifene when used together.”

“We are motivated that with further research and clinical trials, Bazedoxifene could be an important addition to our arsenal in our fight against colorectal cancer.

This ground-breaking study was a multi-institutional collaboration between La Trobe University, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Bio21 Institute, St. Vincent’s Institute of Medical Research and the Barcelona Institute of Science and Technology